Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ___________________________________________________________________ FORM 10-Q ___________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |------------ ...

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Q2 2020 Results Conference Call August 10, 2020 4:30 PM ET Company Participants Myesha Lacy - Investor Relations & Corporate Communications Laurent Fischer - Chief Executive Officer Arshad Khanani - MD and Director of Clinical Research of Sierra Eye Associates Aaron Osborne - Chief Medical Officer Leone Patterson - President Conference Call Participants Tyler Van Buren - Piper Sandler Alethia Young - Cantor Fitzgerald Phil Nadeau - Cowen & Co Graig Suvannavejh - ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ___________________________________________________________________ FORM 10-Q ___________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm ...

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Q1 2020 Earnings Conference Call May 28, 2020 4:30 PM ET Company Participants Myesha Lacy - Vice President of Investor Relations & Corporate Communications Leone Patterson - President & Chief Executive Officer Aaron Osborne - Chief Medical Officer Conference Call Participants Tyler Van Buren - Piper Sandler Phil Nadeau - Cowen & Company Alethia Young - Cantor Mani Foroohar - SVB Leerink Graig Suvannavejh - Goldman Sachs Luca Issi - RBC Capital Markets Valentyna C ...

| --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|----------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Transforming Gene Therapy | | | | | | Agenda & Participants Agenda • Corporate update • Progress advancing lead gene therapy candidate ADVM-022: o Data and enrollment highlights from OPTIC Phase 1 Clinical Trial of ADVM-022 in wet AMD o New INFINITY Phase 2 Clinical Trial of ADVM-022 in Diabetic Macular Edema • Q& ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ___________________________________________________________________ FORM 10-Q ___________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Com ...

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Q4 2019 Earnings Conference Call March 12, 2020 4:30 PM ET Company Participants Myesha Lacy - Vice President of Investor Relations and Corporate Communications Leone Patterson - President and Chief Executive Officer Aaron Osborne - Chief Medical Officer Thomas Leung - Chief Financial Officer Conference Call Participants Alethia Young - Cantor Tara Bancroft - Piper Sandler Phil Nadeau - Cowen & Co Patrick Dolezal - LifeSci Capital Operator Adverum Biotechnologies a ...